Carvedilol Phosphate Hemihydrate CAS 610309-89-2 Purity >99.0% (HPLC)

Carvedilol Phosphate Hemihydrate (CAS: 610309-89-2) is a selective blocking α1-receptor and non-selective β-receptor blocker, no intrinsic Sympathimetic active drugs, bioavailability of 10 ~ 47%, not affected by food, the effect on α1-receptor is significantly lower than β1-and β2-receptor, the intensity ratio of β 1-and β 2-receptor blockade is 1:10~1:100. The effect of β 1-receptor blockade is about 1/2 of labetalol, and its α1 blockade is weaker than prazosin. It can dilate blood vessels, reduce peripheral vascular resistance, dilate coronary and renal vessels, and reduce pulmonary wedge pressure. It has obvious protective effect on myocardial hypoxia and myocardial injury caused by myocardial infarction, which may be related to blocking β-receptor, which can reduce the decrease of myocardial glycogen and the increase of pH, and reduce the infarct size.
Carvedilol Phosphate Hemihydrate is used to treat mild to moderate hypertension and can be used alone or in combination with other antihypertensive drugs (especially thiazide diuretics). For symptomatic chronic congestive heart failure.
Carvedilol Phosphate Hemihydrate is a non-selective β/α-1 receptor blocker. Carvedilol inhibit lipid peroxidation with an IC50 of 5 μM. Carvedilol is a multi-purpose antihypertensive agent with potential for the study of angina pectoris and congestive heart failure.